VasoGenix
Lenexa
About VasoGenix
VasoGenix Pharmaceuticals, Inc., is developing intravenous (IV) and controlled release drug treatments for addressing Heart Failure ("HF") and other cardiac diseases in order to reduce the recurrence of these diseases and their resulting hospital and medical costs. VasoGenix is initially focusing on a major unmet critical need in Acute Decompensated Heart Failure ("ADHF"), when the symptoms of HF become severe enough to require hospitalization.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $410.0K
- Last round: Convertible Note (Dec 2010)
- Website: vasogenix.net
- Phone: (913)888-4773
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/vasogenix-2162921 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.